Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02851342
Other study ID # BRUMEG
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 2016
Est. completion date January 2019

Study information

Verified date November 2020
Source Universitair Ziekenhuis Brussel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. The primary hypothesis for the study is: Interhemispheric connectivity, determined using graph theoretic analysis (GTA) on source-reconstructed MEG data, is a biomarker for cognitive deterioration in MS, which has value at the individual patient level.


Description:

Procedures Clinical assessment - Disease type (Progressive onset/Relapsing onset) - Disease phase (onset, relapsing remitting, secondary progressive, …) - EDSS measurement (standard in the neurological examination) - Time since last relapse (important for the exclusion criteria) - Medication - Level of education - Pre-morbid Intelligence Quotient (IQ) Symbol Digit Modalities Test (SDMT) - screening - General - In the final design of this study, the investigators will screen our patient group using the Symbol Digit Modalities Test (SDMT), a fast (5 min) and easy test that has been shown to be predictive of general cognitive impairment in MS probably due to the importance of information processing speed in cognitive deterioration in MS. - This screening procedure will allow us to include an 'enriched' sample of MS patients; i.e. including patients with different cognitive abilities will allow us to assess correlations between brain network organization and cognition over a broader range of cognitive abilities. MEG/EEG assessment - General - The subjects are asked to come to the MEG unit in the Université libre de Bruxelles (ULB) Erasmus Hospital in Anderlecht - MEG measurements will be obtained using a Neuromag-306 Vector View system (Elekta). This scanner has 306 channels: 102 pairs of orthogonal planar gradiometers and 102 magnetometers. To aid artifact detection, electrooculograms (EOG) and electrocardiograms (ECG) were also recorded. Sampling frequency is 1000 Hertz (HZ). - Subjects will be monitored for excessive eye-blinks. Although methods as independent component analysis (ICA) can remove these artefacts to some extent, too many eye-blinks may render the subsequent analyses impossible. - Preparing the subject for the MEG assessment takes about 45 min. - The patient's head movement will be continuously monitored. - Resting-state - Eyes Open 1. 10 min 2. Subjects will be asked to pay attention to a fixation cross - Eyes Closed 1. 10 min 2. Subjects will be asked not to fall asleep - Adjusted SDMT - In this experiment, the patients are shown a code that links the numbers 1-9 to a certain symbol. For each trial, they also see one example that links a number to a symbol and they are asked to press the LEFT button if they think the example conforms with the presented code and the RIGHT button if they think otherwise. Subjects will be given a maximum of 6 s for each decision to be made and response timings will be recorded. The code that is presented varies with every example. This computerized set up of the SDMT was kindly provided by prof. Rypma. There is a pause of 2s between every decoding task. A total of 256 stimuli are presented, half of which are correct. The design follows the design by Leavitt et al. very closely (except for variable the interstimulus interval- 4,8,12 s - that was fixed to 3s in this design. Depending on the speed at which the subjects answers, this paradigm is expected to last between 9 and 10 min. - Practice trial 1. The subjects are shown 10 trials and their response is monitored. In this step, the researcher checks if the subject understands the paradigm. - Actual paradigm 1. The patients will be shown 256 trials, 50 % of which are correct. 2. The total time for this experiment (at a speed of 2s per decision is : 9 min). 3. The subjects won't receive any feedback from this part. - A small break of 10 minutes in order not to fatigue the subjects too much. - Auditory P300 paradigm - The subjects are asked to press a button when they hear a high-pitched tone among a series of standard tones. The interstimulus interval will randomly shift between 1 and 1.5 s. - Practice trial 1. Subjects will first hear the standard tone 10 times (1000 Hz) 2. Subjects will hear the target (high-pitched, 1500 Hz) tone 2 times 3. Subjects will hear the distractor tone (500 Hz) 2 times 4. The interstimulus interval will be sampled from the same distribution as the interstimulus interval used in the actual test 5. Patients are not asked to press any buttons in this part. - Actual test 1. The subjects will hear a series of 400 tones. The total test time is therefore 8m20. - 80 % of the tones will be frequent tones - 10 % of the tones will be target tones, for which the subjects are asked to press a button - 10 % of the tones will be distractor tones. Subjects are asked not to press any button in case of these distractor tones. - The subjects won't get any feedback on their performance - N-back test - In the N-back test, a subjects sees a series of numbers (1-4) and is asked to compare the current stimulus to the N'th previous stimulus. In the case of a zero-back experiment, the subjects are asked to press a button when they see a certain number (e.g. 2). - The experiment is designed as follows. There are three conditions imposing different loads on working memory (0-,1- and 2-back tasks). Each block lasts 30 s and there are eight blocks for each condition. The total registration time is therefore 12 min. The experiment is designed in agreement with the literature. - Before the actual experiment, there will be a small practice trial including the three blocks (0-, 1- and 2-back task). This lasts approximately 2 min. - Possible confounders: - General: 1. These confounders are to be administered right after the MEG recordings. 2. These confounders are important as they may influence the cognitive results obtained during the MEG. - Depression (Beck Depression Inventory) - Fatigue (Fatigue scale for Motor and Cognitive Functions, FSMC) - Brief International Cognitive Assessment for MS (BICAMS) - (2) MRI assessment - The informed consent asks for permission to analyse the T1 and T2 image, two images included in the standard clinical protocol, in the data analysis for the study. Furthermore, we will acquire and analyse a diffusor tensor imaging (DTI) measurement and a resting-state functional MRI image.


Recruitment information / eligibility

Status Completed
Enrollment 159
Est. completion date January 2019
Est. primary completion date January 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Multiple sclerosis according to the modified McDonald criteria - Expanded Disability Status Scale (EDSS) below 6.0 - Providing informed consent - Age between 18 and 55 years Exclusion Criteria: • Major medical or psychiatric pathology that potentially influences cognition

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Belgium National MS Center Melsbroek Melsbroek Vlaams Brabant

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary MEG Contrasts of parameter estimates (COPE) Contrasts (first-level or group-level) of parameter estimates based on averaged measured magnetic activity. 0 to 1000 msec post stimulus
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis